StockStory.org on MSN
NEO Q1 deep dive: High-value test expansion and commercial execution drive oncology growth
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q1 CY2026 results , with sales up 11.1% year on year ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the testing & diagnostics services stocks, including NeoGenomics (NASDAQ:NEO) and its peers. The testing and diagnostics services ...
Gehost op MSN
Testing & Diagnostics Services Stocks Q2 Teardown: NeoGenomics (NASDAQ:NEO) Vs The Rest
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q2, starting ...
FORT MYERS - NeoGenomics, Inc. (NASDAQ:NEO), a diagnostics company generating annual revenue of $672 million with 10.1% year-over-year growth, has launched NEO PanTracer LBx, a blood-based ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Sommige resultaten zijn verborgen omdat ze mogelijk niet toegankelijk zijn voor u.
Niet-toegankelijke resultaten weergeven